Sihuan Pharm (00460.HK) announced on June 27th that its non-wholly-owned subsidiary, Huisheng Biopharmaceuticals Co., Ltd. ("Huisheng Biopharm"), has received the drug registration certificate issued by the National Medical Products Administration (NMPA) of China for its Hydroxyethyl calcium sulfate capsules. The product is deemed to have passed the consistent evaluation on the quality and efficacy of generic drugs.

Hydroxyethyl calcium sulfate is a capillary protector used to improve microcirculation by regulating the physiological function of microvascular walls, increasing permeability, reducing resistance, lowering plasma viscosity, and decreasing platelet aggregation, thus preventing thrombosis and improving the flexibility of red blood cells. Hydroxyethyl calcium sulfate is recommended in the Chinese clinical guideline for improving microcirculation in diabetic patients. Hydroxyethyl calcium sulfate capsules are listed as National Medical Insurance Category B drugs. The approved indications for this product are: treatment of microvascular diseases such as diabetic microvascular lesions - retinopathy and glomerulosclerosis, microvascular injury, etc.